Vergelijking
Liraglutide vs. Maridebart Cafraglutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
204656-20-2
geen gegevens
Molecuulmassa
3751 g/mol
geen gegevens
Halfwaardetijd
13 h
geen gegevens
Sequentie
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGgeen gegevens
Werkingsmechanisme
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
1
waarvan bij mensen
4
1
Geregistreerde effecten
3
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Liraglutide and Maridebart Cafraglutide?
- Liraglutide is classified as "Metabool", while Maridebart Cafraglutide is classified as "Metabool". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Maridebart Cafraglutide?
- The highest available evidence level is "Humane RCT" for Liraglutide and "Humane RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Maridebart Cafraglutide in Germany and the United States?
- Duitsland: Liraglutide — Op recept, Maridebart Cafraglutide — Niet goedgekeurd. Verenigde Staten: Liraglutide — Op recept, Maridebart Cafraglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.